Literature DB >> 6745850

Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis.

A J Czaja, G L Davis, J Ludwig, H F Taswell.   

Abstract

To assess the frequency and significance of complete resolution of inflammatory activity following corticosteroid therapy, 115 patients with severe HBsAg-negative chronic active hepatitis were followed regularly for 84 +/- 5 months. Of 83 patients eligible to revert to normal liver tissue, 18 did so after 56 +/- 8 months. Five of the 18 relapsed after treatment withdrawal. Only patients who improved spontaneously after cessation of treatment from histologic features of chronic persistent hepatitis to normal invariably sustained the improvement. Of 32 patients with cirrhosis at presentation, 17 reverted to inactive cirrhosis after 48 +/- 10 months, but only 3 remained inactive after discontinuation of treatment. Mortality was similar in patients with and without reversion to normal tissue (0 vs. 14%, p greater than 0.2), but the frequency of relapse was less after complete resolution (28 vs. 76%, p less than 0.001). Reversion to inactive cirrhosis did not improve survival or reduce relapse frequency after remission and treatment withdrawal. Findings prior to therapy did not predict outcome. We conclude that complete resolution of inflammatory activity is possible, but that it occurs slowly, infrequently and unpredictably after therapy. In patients without cirrhosis, reversion to normal liver tissue decreases the likelihood of relapse and the requirement for retreatment. In patients with cirrhosis at presentation, elimination of inflammatory activity is rarely sustained and does not improve prognosis after remission and treatment withdrawal.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6745850     DOI: 10.1002/hep.1840040409

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis.

Authors:  Michael W Milks; James G Cripps; Heping Lin; Jing Wang; Richard T Robinson; Jennifer L Sargent; Michael L Whitfield; James D Gorham
Journal:  Liver Int       Date:  2009-04-16       Impact factor: 5.828

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

4.  Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis.

Authors:  R Malekzadeh; S Nasseri-Moghaddam; M J Kaviani; H Taheri; N Kamalian; M Sotoudeh
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

Review 5.  Chronic hepatitis: a review.

Authors:  R A Bradbear
Journal:  J R Soc Med       Date:  1985-05       Impact factor: 5.344

Review 6.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

Review 7.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

8.  Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 9.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

10.  Long-term treatment outcomes for autoimmune hepatitis in Korea.

Authors:  Jae Sook Kil; Joon Hyoek Lee; A-Reum Han; Ja Young Kang; Hye Jin Won; Han Young Jung; Hyun Min Lim; Geum-Youn Gwak; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.